Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson's disease based on [123I]FP-CIT SPECT images

Purpose This work aimed to assess the potential of a set of features extracted from [I-123] FP-CIT SPECT brain images to be used in the computer-aided "in vivo" confirmation of dopaminergic degeneration and therefore to assist clinical decision to diagnose Parkinson's disease.Methods Seven features were computed from each brain hemisphere: five standard features related to uptake ratios on the striatum and two features related to the estimated volume and length of the striatal region with normal uptake. The features were tested on a dataset of 652 [I-123] FP-CIT SPECT brain images from the Parkinson's Progression Markers Initiative. The discrimination capacities of each feature individually and groups of features were assessed using three different machine learning techniques: support vector machines (SVM), k-nearest neighbors and logistic regression.Results Cross-validation results based on SVM have shown that, individually, the features that generated the highest accuracies were the length of the striatal region (96.5%), the putaminal binding potential (95.4%) and the striatal binding potential (93.9%) with no statistically significant differences among them. The highest classification accuracy was obtained using all features simultaneously (accuracy 97.9%, sensitivity 98% and specificity 97.6%). Generally, slightly better results were obtained using the SVM with no statistically significant difference to the other classifiers for most of the features.Conclusions The length of the striatal region uptake is clinically useful and highly valuable to confirm dopaminergic degeneration "in vivo" as an aid to the diagnosis of Parkinson's disease. It compares fairly well to the standard uptake ratio-based features, reaching, at least, similar accuracies and is easier to obtain automatically. Thus, we propose its day to day clinical use, jointly with the uptake ratio-based features, in the computer-aided diagnosis of dopaminergic degeneration in Parkinson's disease

Decoding the dopamine transporter imaging for the differential diagnosis of parkinsonism using deep learning.

PURPOSE This work attempts to decode the discriminative information in dopamine transporter (DAT) imaging using deep learning for the differential diagnosis of parkinsonism. METHODS This study involved 1017 subjects who underwent DAT PET imaging ([11C]CFT) including 43 healthy subjects and 974 parkinsonian patients with idiopathic Parkinson's disease (IPD), multiple system atrophy (MSA) or progressive supranuclear palsy (PSP). We developed a 3D deep convolutional neural network to learn distinguishable DAT features for the differential diagnosis of parkinsonism. A full-gradient saliency map approach was employed to investigate the functional basis related to the decision mechanism of the network. Furthermore, deep-learning-guided radiomics features and quantitative analysis were compared with their conventional counterparts to further interpret the performance of deep learning. RESULTS The proposed network achieved area under the curve of 0.953 (sensitivity 87.7%, specificity 93.2%), 0.948 (sensitivity 93.7%, specificity 97.5%), and 0.900 (sensitivity 81.5%, specificity 93.7%) in the cross-validation, together with sensitivity of 90.7%, 84.1%, 78.6% and specificity of 88.4%, 97.5% 93.3% in the blind test for the differential diagnosis of IPD, MSA and PSP, respectively. The saliency map demonstrated the most contributed areas determining the diagnosis located at parkinsonism-related regions, e.g., putamen, caudate and midbrain. The deep-learning-guided binding ratios showed significant differences among IPD, MSA and PSP groups (P < 0.001), while the conventional putamen and caudate binding ratios had no significant difference between IPD and MSA (P = 0.24 and P = 0.30). Furthermore, compared to conventional radiomics features, there existed average above 78.1% more deep-learning-guided radiomics features that had significant differences among IPD, MSA and PSP. CONCLUSION This study suggested the developed deep neural network can decode in-depth information from DAT and showed potential to assist the differential diagnosis of parkinsonism. The functional regions supporting the diagnosis decision were generally consistent with known parkinsonian pathology but provided more specific guidance for feature selection and quantitative analysis

Clinical correlates and advanced processing of the dopamine transporter spect - applications in parkinsonism.

La visualización del transportador de dopamina (DAT) a través del SPECT con [123I]FP-CIT es una prueba de imagen ampliamente usada en el diagnóstico de la enfermedad de Parkinson (EP) y otros trastornos del movimiento que cursan con síntomas parkinsonianos. Dicha imagen permite visualizar y cuantificar los niveles de DAT en el estriado y sus regiones putamen y caudado, y es por tanto una herramienta útil para evaluar in-vivo el estado de las terminales presinápticos dopaminérgicos de la vía nigroestriada. En la práctica clínica es comúnmente utilizado para la diferenciación de parkinsonismos neurodegenerativos con afectación presináptica y otros trastornos del movimiento con síntomas similares pero sin afectación presináptica como el temblor esencial. En la imagen se suele observar un patrón de degeneración postero-anterior que se corresponde con la progresión de síntomas en la EP debido a la afectación progresiva de los circuitos de los ganglios basales. De hecho, numerosos estudios han mostrado que la falta de DAT en el putamen y caudado se correlacionan con síntomas motores y cognitivos, respectivamente. Sin embargo, a pesar de su uso extendido, su uso clínico dado los métodos de evaluación actuales se limita a determinar la presencia o no de degeneración nigroestriada. En esta tesis se plantea como hipótesis que el uso de métodos de procesamiento y evaluación más sofisticados, utilizando técnicas de procesamiento de imágenes y de reconocimiento de patrones a nivel de vóxel, podría potenciar el desarrollo de nuevas aplicaciones clínicas; incluyendo la evaluación de síntomas y el diagnóstico diferencial entre parkinsonismos. Para ello, hemos caracterizado clínicamente y recogido imágenes de SPECT de cientos de pacientes con EP y otros parkinsonismos, persiguiendo dos objetivos globales: i) investigar ciertos conceptos actuales sobre los síntomas motores y cognitivos en la EP; y ii) desarrollar nuevos métodos de procesamiento y evaluación que permitan extender el rango actual de aplicaciones clínicas de dicha prueba. Se presentan un total de 5 publicaciones agrupadas en dos temáticas, una para cada objetivo global. En la primera temática, se engloban dos trabajos con títulos: 1) Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype, Plos One 2017 Mar 30;12(3):e0174644; y 2) Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease, Plos One 2017 Apr 11;12(4):e0175560. En el trabajo 1 se investigaron las diferencias entre los niveles de ácido úrico y dopamina estriatal en los subtipos motores de EP: tremorígeno, intermedio, y con trastorno de la marcha e inestabilidad postural. Estudiamos 75 pacientes con EP de larga evolución y encontramos que aquellos que presentaron un predominio de temblor al inicio y mantuvieron este fenotípo clinico durante el curso de la enfermedad, tuvieron niveles de ácido úrico y dopamina estriatal mayores que aquellos que desarrollaron trastorno de la marcha e inestabilidad postural. Además, los niveles de ácido úrico y de dopamina estriatal se correlacionaron. Como conclusión, especulamos que niveles bajos de este antioxidante natural (el ácido úrico) puede reducer los niveles de neuroprotección y por tanto influenciar el perfil y curso de fenotipo motor en la EP. En el trabajo 2 se investigó la contribución de los principales factores genéticos descritos en la literatura en los síndromes duales de deterioro cognitivo en la EP (fronto-estriatal que conlleva un alto riesgo de síndrome disejecutivo – causado por falta de dopamina – y posterior-cortical que conlleva un alto riesgo de demencia). Evaluamos la imagen, el estado cognitivo y el genotipo de 298 pacientes con EP. Como resultado, observamos que el alelo APOE2, los polimorfismos SNCA rs356219 y COMT Val158Met, y las variantes patogénicas en GBA se asociaron con los niveles de denervación dopaminérgica estriatal, mientras que el alelo APOE4 y de nuevo las variaciones patogénicas en GBA se asociaron con el desarrollo de demencia (sugiriendo un doble rol del gen GBA). No encontramos ninguna relación del haplotipo MAPT H1 en ninguno de los síndromes. Concluimos que la dicotomía de los síndromes duales puede estar conducida por una dicotomía en estos factores genéticos. En la segunda temática, se presentan otros 3 trabajos más centrados en el desarrollo de metodología, titulados: 3) Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [123I]FP-CIT SPECT, European Journal of Nuclear Medicine and Molecular Imaging, 2015 Jan;42(1):112-9; 4) A Bayesian spatial model for neuroimaging using multiscale functional parcellations, En revisión en la revista euroimage; y un último trabajo que está en elaboración y cuyos resultados preliminares fueron presentados recientemente: 5) Probabilistic intensity normalization of PET/SPECT images via Variational mixture of Gamma distributions, 30th Neural Information and Processing Systems Conference, November 2016, Barcelona, Spain. En el trabajo 3 se desarrollaron algoritmos usando imágenes de SPECT para distinguir un parkinsonismo secundario – el parkinsonismo vascular (PV) – de la EP. Observamos que una simple regresión logística – incluyendo los valores medios de captación estriatales, junto con el sexo, la edad, y los años de evolución – diferenció ambas entidades con un 90% de exactitud. De manera similar, encontramos que el uso de algoritmos objetivos y automáticos usando técnicas de machine learning basadas en vóxeles también discriminaron ambas entidades con un 90% de exactitud. Concluimos que el diagnóstico diferencial de ambas enfermedades puede ser asistido por algoritmos automáticos basados en imagen. En el trabajo 4 se desarrolló una nueva metodología, más allá del método estándar basado en vóxeles, para realizar inferencias en neuroimagen funcional. Se desarrolló un modelo multivariado espacial que permitió modelar imágenes de SPECT de sujetos sanos de manera muy eficiente con un número de parámetros muy inferior al número de vóxeles. Dicho modelo consiste en una superposición lineal de funciones base utilizando subparcelaciones multi-escala del estriado, éstas obtenidas tras procesar imágenes de resonancia magnética funcional. También demostramos la utilidad de nuestro modelo para desarrollar aplicaciones clínicas mediante la construcción de clasificadores para diferenciar la EP de controles sanos y un parkinsonismo atípico: la parálisis supranuclear progresiva. Esta nueva metodología ofrece ventajas sin precedentes para el análisis de neuroimagen con respecto al clásico modelo lineal general univariado basado en vóxel, incluyendo: i) mayor interpretabilidad de las señales cerebrales; ii) modelos parsimoniosos y por tanto incremento del poder estadístico; y iii) modelado de la correlación espacial entre regiones y a distintos niveles de granuralidad en neuroimagen funcional. Además, desarrollamos metodología bayesiana para detectar de manera automática (y cuantificar la incertidumbre) las regiones cerebrales que estén relacionadas con ciertas variables fenotípicas. En el trabajo 5 se desarrolló un método para armonizar la intensidad de las imágenes de SPECT producidas por distintos fabricantes (y calibración) de cámaras Gamma. El método se basa en modelar el histograma de la imagen con un modelo mixto de distribuciones Gamma. Se utilizó la función de densidad acumulada de la distribución Gamma que modela la región específica de captación para reparametrizar la imagen con valores de vóxel entre 0 y 1. Observamos que dicha normalización mejoró sustancialmente (hasta un 10%) el diagnóstico de EP cuando los algoritmos se desarrollaron usando imágenes de distintas cámaras y/o calibraciones. Dicha normalización puede suponer un paso clave en pre-procesado de estas imágenes de cara a la realización de estudios multicéntricos y el desarrollo de aplicaciones clínicas generalizables. Como conclusión es importante resaltar la relevancia de los trabajos. En los trabajos 1 y 2 hemos aportado resultados con biomarcadores de valor pronóstico en la progresión de la EP. En los trabajos 3, 4 y 5, hemos aportado una nueva metodología, muy superior a la existente, de procesamiento y evaluación de esta prueba de imagen. La metodología desarrollada en el trabajo 4 permite explorar regiones cerebrales a un de nivel de complejidad espacial y granularidad sin precedentes. Por ello, nuestro modelo podría captar las diferencias entre las imágenes de pacientes con distintas patologías y/o entre síntomas específicos residir en patrones espaciales sutiles y complejos. De hecho, en los trabajos 3 y 4 aportamos resultados excelentes en la diferenciación de la EP con otros síndromes parkinsonianos. Además, el trabajo 5 tiene el potencial de constituirse en el campo como un paso fundamental de pre-procesado, especialmente en estudios ulticéntricos y estudios que pretendan desarrollar aplicaciones clínicas generalizables, independientemente de la cámara Gamma y el centro donde se realice la prueba. Es importante señalar además que los métodos desarrollados se podrían igualmente aplicar para procesar y evaluar otro tipo de imágenes de medicina nuclear y/u otras regiones cerebrales. Es por ello que esperamos que este trabajo tenga un gran impacto en general en la evaluación de este tipo de imágenes y en el desarrollo de algoritmos que den soporte a la decisiones clínicas en trastornos del movimiento y potencialmente en otras enfermedades.The imaging of the dopamine transporter (DAT) with [123I]FP-CIT SPECT is a routinely used assessment in the diagnostic pipeline of Parkinson’s disease (PD) and other movement disorders that present with parkinsonian symptoms. In this scan, the levels of striatal DAT can be visualized and quantified, also at the region-of-interest (ROI) level in putamen and caudate, and therefore it constitutes an useful tool to assess in-vivo the state of the dopaminergic presynaptic terminals in the nigrostriatal pathway. In routine clinical practice it is especially utilized for the differential diagnlosis of presynaptic neurodegenerative disorders like PD and other non-presynaptic movement disorders like essential tremor. Also, numerous research studies have shown that striatal DAT deficits quantitatively correlate with motor and cognitive impairment in PD. Indeed, it can be seen in the image a posterior-to-anterior pattern of degeneration that well corresponds with disease progression due to the progressive lost of dopaminergic input into the motor and associative loops between the basal ganglia and the cortex. However, despite its known utility and widespread availability, its use with current assessment methods in real clinical practice is limited to determining the presence of nigrostriatal degeneration at a single-subject level in a binary fashion. We hypothesized in this thesis that an enhanced processing and assessment of this scan with modern image processing and pattern recognition techniques may help to boost its use in the clinic with new and more accurate applications, including symptom risk assessment and differential diagnosis with other parkinsonisms. We collected DAT scans of several hundreds of well-clinicallyphenotyped patients with PD and other parkinsonims, envisaging two main global objectives: i) to investigate some trending hypotheses and concepts about the motor and cognitive impairment in PD; and ii) to develop new processing and evaluation strategies with computational techniques to shed light into new clinical applications. A total of 5 publications are herein presented and grouped in two themes, one for each global objective. In the first theme, two works are presented, entitled: 1) Lower levels of uric acid and striatal dopamine in non-tremor dominant Parkinson's disease subtype, Plos One 2017 Mar 30;12(3):e0174644; and 2) Genetic factors influencing frontostriatal dysfunction and the development of dementia in Parkinson's disease, Plos One 2017 Apr 11;12(4):e0175560. In work 1 we investigated the differences in uric acid and striatal DAT in PD motor subtypes: tremor-dominant, intermediate, or postural instability and gait disorder (PIGD). We studied 75 PD patients of long-term evolution and found that those who presented with a tremor onset and maintained predominance of tremor, or, to a lesser extent, evolved to an intermediate phenotype, had higher levels of uric acid and striatal DAT binding than those who developed a IGD phenotype. We also found that uric acid and striatal DAT levels were highly correlated. We speculate that low levels of this natural antioxidant may lead to a lesser degree of neuroprotection and could therefore influence the motor phenotype and course. In work 2 we investigated the contribution to the dual syndromes of cognitive impairment in PD (frontostriatal dopamine-mediated and posterior cortical leading to dementia) of the main genetic risk factors decribed in the literature. We evaluated the scans, the cognitive status, and the genotypes of 298 PD patients and found that APOE2 allele, SNCA rs356219 and COMT Val158Met polymorphisms, and deleterious variants in GBA influenced striatal dopaminergic depletion, and that APOE4 allele and deleterious variants in GBA influenced dementia, thus suggesting a doubleedged role for GBA. We did not found any role of MAPT H1 haplotype. We conclude that the dichotomy of the dual syndromes may be driven by a broad dichotomy in these genetic factors. In the second theme, we present three other works with more focus on methodology, entitled: 3) Machine learning models for the differential diagnosis of vascular parkinsonism and Parkinson's disease using [123I]FP-CIT SPECT, European Journal of Nuclear Medicine and Molecular Imaging, 2015 Jan;42(1):112-9; 4) A Bayesian spatial model for neuroimaging using multiscale functional parcellations, Under Review in Neuroimage; and a last piece of work that it is in preparation for submission and that I have adapted for this thesis from 5) Probabilistic intensity normalization of PET/SPECT images via Variational mixture of Gamma distributions, 30th Neural Information and Processing Systems Conference, November 2016, Barcelona, Spain. In work 3 we developed analytical models using DAT SPECT data to discriminate vascular parkinsonism (VP) from PD. We collected scans from 80 VP and 164 PD and found that a simple logistic regression using the quantification of the striatal subregions putamen and caudate together with age, sex and disease duration discriminated both entities with over 90% accuracy. Also, we found that the use of more automated and rater-independent machine learning algorithms such as support vector machines with the voxel-wise data of the striatum also gives discrimination accuracy over 90%. We conclude that the differential diagnosis of both diseases can be aided by automated image-based algorithms. In work 4 we developed a new anaylsis framework to perform inferences with functional neuroimaging data. We developed a multivariate spatial model by which an imaged brain region can be efficiently represented in low dimensions with a linear superposition of basis functions. To demonstrate, we accurately modeled DATSCAN images from healthy subjects with a linear combination of multi-resolutional striatum parcellations derived from functional MRI experiments. We also demonstrate the utility of our model to develop clinical application by constructing accurate classifiers to differentiate PD from normal controls and patients with an atypical parkinsonism: the progressive supranuclear palsy. This approach offers unprecedent benefits with respect to classical univariate voxel methods, including: i) greater biological interpretability of the detected brain signals ii) parsimonity in the models and hence gain in statistical power; and iii) multi-range modeling of the spatial dependencies in brain images. Furthermore, we provide a bayesian analysis framework to automatically identifying brain subregions/subnetworks that are meaningful for particular phenotypic variables. In work 5 we developed a voxel-based intensity normalization method for DAT SPECT images aiming at overcoming the liminations of the current ROI-based normalization standard, namely ROI delineation dependence and intensity values dependence on Gamma camera. We found that the intensity histogram of a DAT SPECT image can be modeled as a mixture model of Gamma distributions. The cumulative distribution function (CDF) of the fitted Gamma distributions can be used to re-cast the voxel intensity values into a new normalized feature space between 0 and 1. We found that this re-parametrization equalized intensity across cameras and drastically improved the accuracy of PD diagnosis (up to 10%) when images from different cameras were pooled. Importantly, our method may constitute a key pre-processing step for group-level and multi-center studies. As a final remark, it is important to stress the relevance of the work. In the works 1 and 2, we have provided new insights on biomarkers that have prognostic value in the progression of PD. In the works 3, 4 and 5, which set the grounds of a new powerful approach to process and evaluate these images. The machine learning framework developed in work 4) allows to exploring brain regions at a unprecedent level of spatial complexity and granurality. Thus, challenging tasks such as the differential diagnosis between different parkinsonian disorders or the identification of fine-grained regions/networks responsible for specific parkinsonian symptoms can be tackled with the proposed approach. In fact, we obtained excellent results in works 3 and 4 in the differentiation of PD from other parkinsonian syndromes. Also, the work 5 may constitute a fundamental pre-processing step, especially in multi-center studies and studies aiming at developing generalizable clinical applications, regardless of the Gamma camera manufacturer and site where the scan is made. It is important to note that, besides DATSCAN, these methods could be also applied to other nuclearmedicine images and/or brain regions. We hope that this work will have an impact in the assessment of this type of images and in the development of algorithms supporting clinical decisions in movement disorders and potentially in other diseases as well.Premio Extraordinario de Doctorado U

Nonlinear Weighting Ensemble Learning Model to Diagnose Parkinson's Disease Using Multimodal Data

This work was supported by the FEDER/Junta deAndalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades/Proyecto (B-TIC-586-UGR20); the MCIN/AEI/10.13039/501100011033/ and FEDER \Una manerade hacer Europa" under the RTI2018-098913-B100 project, by the Consejeria de Economia, Innovacion,Ciencia y Empleo (Junta de Andalucia) and FEDER under CV20-45250, A-TIC-080-UGR18 and P20-00525 projects. Grant by F.J.M.M. RYC2021-030875-I funded by MCIN/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. Work by D.C.B. is supported by the MCIN/AEI/FJC2021-048082-I Juan de la Cierva Formacion'. Work by J.E.A. is supported by Next Generation EU Fund through a Margarita Salas Grant, and work by C.J.M. is supported by Ministerio de Universidades under the FPU18/04902 grant.Parkinson's Disease (PD) is the second most prevalent neurodegenerative disorder among adults. Although its triggers are still not clear, they may be due to a combination of different types of biomarkers measured through medical imaging, metabolomics, proteomics or genetics, among others. In this context, we have proposed a Computer-Aided Diagnosis (CAD) system that combines structural and functional imaging data from subjects in Parkinson's Progression Markers Initiative dataset by means of an Ensemble Learning methodology trained to identify and penalize input sources with low classification rates and/or high-variability. This proposal improves results published in recent years and provides an accurate solution not only from the point of view of image preprocessing (including a comparison between different intensity preservation techniques), but also in terms of dimensionality reduction methods (Isomap). In addition, we have also introduced a bagging classification schema for scenarios with unbalanced data.As shown by our results, the CAD proposal is able to detect PD with 96.48% of balanced accuracy, and opens up the possibility of combining any number of input data sources relevant for PD.FEDER/Junta deAndalucia-Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades/Proyecto B-TIC-586-UGR20MCIN/AEI P20-00525FEDER \Una manerade hacer Europa RYC2021-030875-IJunta de AndaluciaEuropean Union (EU) Spanish Government RTI2018-098913-B100, CV20-45250, A-TIC-080-UGR18European Union (EU)Juan de la Cierva FormacionNext Generation EU Fund through a Margarita Salas GrantMinisterio de Universidades FPU18/0490

The role of serotonergic and dopaminergic mechanisms and their interaction in Levodopa-induced dyskinesias

Long–term levodopa treatment in Parkinson’s disease (PD) is commonly associated with troublesome levodopa–induced dyskinesias (LIDs). Striatal serotonergic terminals amid the degenerating dopaminergic ones are proposed to play an important role in LIDs by taking up exogenous levodopa and releasing dopamine in an unregulated fashion. However, to date, the underlying mechanisms of LIDs are not fully understood. By using single photon emission computed tomography (SPECT) with 123I–Ioflupane and positron emission tomography (PET) with 11C–DASB and 11C–PE2I, the clinical studies conducted for this thesis aimed (a) to estimate the role of striatal dopamine transporter (DAT) availability in early PD as a prognostic marker for LIDs, (b) to explore whether striatal DAT availability changes over time are related to the appearance of LIDs, (c) to estimate the role of striatal serotonin-to-dopamine transporter (SERT–to–DAT) binding ratios to LIDs, and (d) to look for a relation between the changes in striatal SERT, DAT and SERT–to–DAT binding ratios over time and the appearance of LIDs. The main findings are as follows: (a) in early PD, striatal DAT availability alone does not predict the appearance of future LIDs, (b) at later stages, the occurrence of LIDs may be dependent on the magnitude of DAT decline in the putamen, (c) the SERT–to–DAT binding ratio in the putamen is increased in PD patients as compared to controls, and within PD, it is higher in patients with LIDs as compared to nondyskinetic patients, (d) as PD continues to progress, putaminal serotonergic terminals remain relatively unchanged in comparison to the dopaminergic ones and the aforementioned imbalance (as reflected by the binding ratio) increases over time. These findings provide fundamental insight in the pathophysiology of LIDs and have direct implications for further research towards novel therapeutics in PD dyskinesia.Open Acces

Classification of patients with parkinsonian syndromes using medical imaging and artificial intelligence algorithms

The distinction of Parkinsonian Syndromes (PS) is challenging due to similarities of symptoms and signs at early stages of disease. Thus, the need of accurate methods for differential diagnosis at those early stages has emerged. To improve the evaluation of medical images, artificial intelligence turns out to be a useful tool. Parkinson’s Disease, the commonest PS, is characterized by the degeneration of dopamine neurons in the substantia nigra which is detected by the dopamine transporter scan (DaTscanTM), a single photon-emission tomography (SPECT) exam that uses of a radiotracer that binds dopamine receptors. In fact, by using such exam it was possible to identify a sub-group of PD patients known as “Scans without evidence of dopaminergic deficit” (SWEDD) that present a normal exam, unlike PD patients. In this study, an approach based on Convolutional Neural Networks (CNNs) was proposed for classifying PD patients, SWEDD patients and healthy subjects using SPECT and Magnetic Resonance Imaging (MRI) images. Then, these images were divided into subsets of slices in the axial view that contains particular regions of interest since 2D images are the norm in clinical practice. The classifier evaluation was performed with Cohen’s Kappa and Receiver Operating Characteristic (ROC) curve. The results obtained allow to conclude that the CNN using imaging information of the Basal Ganglia and the mesencephalon was able to distinguish PD patients from healthy subjects since achieved 97.4% accuracy using MRI and 92.4% accuracy using SPECT, and PD from SWEDD with 97.3% accuracy using MRI and 93.3% accuracy using SPECT. Nonetheless, using the same approach, it was not possible to discriminate SWEDD patients from healthy subjects (60% accuracy) using DaTscanTM and MRI. These results allow to conclude that this approach may be a useful tool to aid in PD diagnosis in the future

Optimized semi-quantitative analysis of dopamine transporter SPECT to support visual image interpretation in the diagnosis of parkinsonian syndromes

Zur Differenzierung von neurodegenerativen und nicht-neurodegenerativen Ursachen eines klinisch unklaren Parkinsonsyndroms wird die Dopamintransporter-SPECT (DAT-SPECT) eingesetzt. Neben der visuellen Bildinterpretation unterstützt die semi-quantitative Analyse der striatalen Dopamintransporter-Verfügbarkeit die Befundung. Die vorliegende Dissertationsschrift fasst drei Studien zusammen, die klinisch relevante Parameter der Bildentstehung und Bildverarbeitung in der semi-quantitativen Analyse der DAT-SPECT identifizierten, optimierten und hinsichtlich ihrer diagnostischen Genauigkeit untersuchten. In der ersten Studie wurde eine vollautomatische Methode zur Abgrenzung der äußeren Kopfkontur als Teil der Schwächungskorrektur nach Chang implementiert und gegenüber einer klinisch etablierten halbautomatischen Methode validiert. Die Auswertung eines multizentrischen Datensatzes ergab, dass beide Methoden zur Kopfabgrenzung sowohl vergleichbare semi-quantitative Werte als auch eine vergleichbare diagnostische Genauigkeit lieferten. Damit kann die vollautomatische Methode für den Einsatz in der klinischen Versorgung empfohlen werden, da keine Interaktion durch den Nutzer erforderlich ist. Die zweite Studie untersuchte zwei Methoden zur semi-quantitativen Abschätzung der Tracer Bindung hinsichtlich ihrer diagnostischen Genauigkeit. Der auflösungsunabhängige specific uptake size index (SUSI) zeigte bei Datenerhebung an unterschiedlichen Kamerasystemen eine höhere diagnostische Genauigkeit als der Standardparameter, das sogenannte specific binding ratio (SBR). Dies ist besonders relevant für multizentrische Studien. Sobald jedoch nur ein Kamerasystem eingesetzt wurde, ist der Standardparameter SBR dem SUSI vorzuziehen, da dieser bei vergleichbarer diagnostischer Performance weniger anfällig gegenüber einer fehlerhaften Abschätzung der nicht-spezifischen Tracer-Bindung in der Referenzregion ist. Ziel der dritten Studie war die Untersuchung des Einflusses der Größe der Normaldatenbank (NDB) auf die diagnostische Genauigkeit einer semi-quantitativen Auswertung der DAT-SPECT. Dabei erfolgte eine Simulation von unterschiedlichen Größen der NDB (n=5, 10, 15, …, 50) durch zufälliges Ziehen aus dem Pool an Kontrollen und Validierung der jeweiligen NDB in der Gesamtkohorte anhand von Klassifizierungsgenauigkeit, Sensitivität und Spezifität. Die Analyse ergab, dass ein Mindestumfang von 25 bis 30 DAT-SPECT-Datensätzen zur Bildung einer NDB notwendig ist. Eine Vergrößerung der NDB über 40 Fälle hinaus führt hingegen zu keiner weiteren relevanten Steigerung der diagnostischen Genauigkeit.Dopamine transporter SPECT (DAT-SPECT) is an established method to differentiate neurodegenerative and non-neurodegenerative causes in clinically uncertain parkinsonian syndromes. Besides visual image interpretation, semi-quantitative analysis of the striatal dopamine transporter availability is used to support medical diagnosis. The present doctoral thesis summarizes three studies that identified, optimized and validated clinically relevant, semi-quantitative parameters of DAT-SPECT image acquisition and processing with reference to their diagnostic accuracy. The first study proposed a fully automatic segmentation method of the outer head contour as a part of attenuation correction according to Chang and validated this method to a well-established semi-automatic method. Both methods for head delineation showed comparable semi-quantitative properties as well as comparable diagnostic accuracy based on multi-center patient data. For this reason, we suggest to use the fully automatic method in clinical patient care since no user interaction is required. A direct comparison of two semi-quantitative methods for estimation of tracer binding in reference to diagnostic accuracy was the aim of the second study. The spatial resolution independent specific uptake size index (SUSI) provided a higher diagnostic accuracy compared to the commonly used parameter, the specific binding ratio (SBR), when image acquisition is performed at various camera systems. This is highly relevant for multi-center image acquisition. However, in single-camera/mono-center settings SBR should be favored over SUSI, since SBR seemed to be less sensitive towards errors of the estimate of non-specific tracer uptake in the reference region with comparable diagnostic performance to SUSI. Rationale of the third study was to evaluate the impact of the size of the normal database (NDB) on the diagnostic performance of semi-quantitative analysis in DAT-SPECT. For it, simulation of NDB with different sizes (n=5, 10, 15, …, 50) by randomly selecting subjects from the subcohort of normal controls was implemented and validation of each particular NDB based on the overall cohort was done concerning diagnostic accuracy, sensitivity and specificity as performance measures. The study results suggested that 25 to 30 DAT-SPECT data sets should be the minimum size of NDB. Increasing the size of NDB beyond 40 data sets provided only very small further improvement in diagnostic accuracy

Diagnosis and Treatment of Parkinson's Disease

Parkinson's disease is diagnosed by history and physical examination and there are no laboratory investigations available to aid the diagnosis of Parkinson's disease. Confirmation of diagnosis of Parkinson's disease thus remains a difficulty. This book brings forth an update of most recent developments made in terms of biomarkers and various imaging techniques with potential use for diagnosing Parkinson's disease. A detailed discussion about the differential diagnosis of Parkinson's disease also follows as Parkinson's disease may be difficult to differentiate from other mimicking conditions at times. As Parkinson's disease affects many systems of human body, a multimodality treatment of this condition is necessary to improve the quality of life of patients. This book provides detailed information on the currently available variety of treatments for Parkinson's disease including pharmacotherapy, physical therapy and surgical treatments of Parkinson's disease. Postoperative care of patients of Parkinson's disease has also been discussed in an organized manner in this text. Clinicians dealing with day to day problems caused by Parkinson's disease as well as other healthcare workers can use beneficial treatment outlines provided in this book